- Report
- July 2024
- 99 Pages
Global
From €3500EUR$3,929USD£3,035GBP
The Nuclear Receptor ROR Gamma market is a subset of the Immune Disorders Drugs market. It focuses on drugs that target the ROR Gamma nuclear receptor, which is involved in the regulation of the immune system. These drugs are used to treat a variety of immune-related disorders, such as autoimmune diseases, allergies, and asthma. They are also being studied for their potential to treat cancer and other diseases.
ROR Gamma drugs are typically administered orally or intravenously, and they can be used in combination with other drugs to maximize their effectiveness. They are generally well-tolerated, with few side effects.
Companies in the Nuclear Receptor ROR Gamma market include AbbVie, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more